Zentalis Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ZNTL Nasdaq 2836 zentalis.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Zentalis Pharmaceuticals, Inc.

Zentalis Strengthens Commercial Leadership with Appointments of Shannon Campbell to Board of Directors and Sarah Kelly as SVP of Commercial Strategy - May 27th, 2026 2:05 pm
Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026 - May 21st, 2026 3:39 pm
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences - May 13th, 2026 2:05 pm
Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress - May 12th, 2026 2:05 pm
Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer - May 5th, 2026 6:00 am
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - May 1st, 2026 3:30 pm
Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer - Apr 21st, 2026 8:27 am
Zentalis (ZNTL) Locks In Its Cancer Drug Dose; Jefferies Raises the Target - Apr 20th, 2026 8:47 am
Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026 - Apr 17th, 2026 1:15 pm
A Look At Zentalis Pharmaceuticals (ZNTL) Valuation After Azenosertib Dose Selection Milestone - Apr 12th, 2026 8:11 pm
Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer - Apr 9th, 2026 6:00 am
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 1st, 2026 3:00 pm
Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates - Mar 26th, 2026 2:05 pm
Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026 - Mar 17th, 2026 2:30 pm
Zentalis Pharmaceuticals Details Azenosertib Path to PROC Approval, DENALI Dose Pick Coming Soon - Feb 16th, 2026 3:09 am
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference - Feb 3rd, 2026 2:05 pm
Mitsui Sumitomo Continues to Build WR Berkley Stake - Jan 13th, 2026 6:45 am
A Look At Zentalis Pharmaceuticals (ZNTL) Valuation After Azenosertib Progress And Insider Buying - Jan 11th, 2026 3:08 pm
Following a 13% decline over last year, recent gains may please Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) institutional owners - Jan 8th, 2026 5:27 am
Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026 - Jan 6th, 2026 6:00 am